Skip to content
Screener

Mirum Pharmaceuticals, Inc. MIRM Q4 2025 Annual earnings

Reported February 25, 2026 · After market close

Revenue$148.9MBeat by $6.4M
EPS-$0.11Miss by $0.13
Revenue estimate$142.5M
EPS estimate$0.02

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$178.1M
EPS estimate-$0.53

Financials

Q4 2025

Income statement

See full
Revenue$148.9M+49.8%
Operating income-$4.6M+81.1%
Net income-$5.7M+75.9%
EPS (diluted)-$0.12+75.5%

Balance sheet

See full
Cash & equivalents$254.4M+25.3%
Total debt$9.7M-0.3%
Total equity$314.7M+39.5%
Total assets$842.8M+25.7%

Cash flow

See full
Operating cash flow$6.1M—
CapEx$600.0K+2,900%
Free cash flow$5.5M—

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$4.08B+106%
Enterprise value$3.84B+114%
P/S7.8×+1.9×

Profitability

See full
Operating margin-4.2%-1.9pp
Net margin-4.5%-2.0pp
FCF margin10.5%—

Returns & leverage

See full
Return on equity-8.6%-3.8pp
Debt / equity0×0.0×
Current ratio2.7×-0.4×

Segments

By product

See full
Livmarli$106.4M+66.0%
Bile Acid Medicines$42.5M+20.4%

FAQ

When did Mirum Pharmaceuticals, Inc. report Q4 2025 earnings?
Mirum Pharmaceuticals, Inc. (MIRM) reported Q4 2025 earnings on February 25, 2026 after market close.
What were Mirum Pharmaceuticals, Inc.'s Q4 2025 revenue and EPS?
Mirum Pharmaceuticals, Inc. reported revenue of $148.9M and eps of $-0.11 for Q4 2025.
Did Mirum Pharmaceuticals, Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $142.5M by $6.4M. EPS missed the consensus estimate of $0.02 by $0.13.
How did Mirum Pharmaceuticals, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 49.8% from $99.4M a year earlier and eps grew 77.6% from $-0.49.
Where can I find Mirum Pharmaceuticals, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001759425-26-000010) and the 10-K periodic report (0001759425-26-000013) directly on SEC EDGAR. The filing index links above go to sec.gov.